Since its founding,ANAC has shown a singular commitment to improving the lives of those affected
by HIV/AIDS. Nowhere is this commitment more fully articulated than in ANAC’s Core Curriculum
for HIV/AIDS Nursing. Drawing from the expertise of frontline clinicians and scholars, the first
two editions of the Core Curriculum provided nurses with the evidence-based knowledge to provide
quality care to the diverse groups that comprise the HIV/AIDS population. In this third edition,
we have endeavored to uphold the standard of excellence set by the editors of the first two
Systemic causes of nonpalpable purpura fall into several categories, and those secondary to clotting disturbances and vascular fragility will be discussed first. The former group includes thrombocytopenia (Chap. 109), abnormal platelet function as is seen in uremia, and clotting factor defects. The initial site of presentation for thrombocytopenia-induced petechiae is the distal lower extremity.
Immune Thrombocytopenic Purpura: Treatment The treatment of ITP utilizes drugs that decrease reticuloendothelial uptake of the antibody-bound platelet and/or decrease antibody production. However, the diagnosis of ITP does not necessarily mean that treatment must be instituted. Patients with platelet counts 30,000/µL appear not to have increased mortality related to the thrombocytopenia.
Thrombotic Thrombocytopenic Purpura TTP and HUS were previously considered overlap syndromes. However, in the past few years the pathophysiology of inherited and idiopathic TTP has become better understood and clearly differs from HUS. TTP was first described in 1924 by Eli Moschcowitz and characterized by a pentad of findings that include microangiopathic hemolytic anemia, thrombocytopenia, renal failure, neurologic findings, and fever. The full-blown syndrome is less commonly seen now, probably due to earlier diagnosis.
This woman has a combination of hemolytic anemia with fragmented RBCs on peripheral smear;
thrombocytopenia; fever; neurologic symptoms; and renal dysfunction -- a classic pentad of
symptoms that characterizes thrombotic thrombocytopenic purpura (TTP). Approximately 90%
of patients will respond to plasmapheresis. Patient should be emergently treated with largevolume
plasmapheresis. Sixty to 80 mL/kg of plasma should be removed and replaced with
fresh-frozen plasma. Treatment should be continued daily until the patient is in complete